Tiger Brokers

Celldex presents Phase 2 barzolvolimab data; CSU complete response reaches 71% at Week 52 due to sustained symptom control

Reuters
Mar 27
Celldex presents Phase 2 barzolvolimab data; CSU complete response reaches 71% at Week 52 due to sustained symptom control
  • Celldex reported additional Phase 2 data for barzolvolimab in chronic spontaneous urticaria and in chronic inducible urticaria (cold urticaria and symptomatic dermographism), and said the results were presented at the 2026 American Academy of Dermatology Annual Meeting.
  • In a post hoc analysis of patients with well-controlled chronic spontaneous urticaria at Week 52, 94% had a Dermatology Life Quality Index (DLQI) score of 0/1 at Week 52.
  • At Week 76, 76% of those patients reported DLQI ≤5.
  • In the Phase 2 cold urticaria and symptomatic dermographism study, barzolvolimab increased the rate of DLQI 0/1 at Week 20 by up to 3.1-fold in cold urticaria and 4.0-fold in symptomatic dermographism versus placebo.
  • The company said quality-of-life improvements were observed across all six DLQI domains, with effects apparent by Week 4 in the 300 mg Q8W dosing group.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603271030PRIMZONEFULLFEED9679628) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10